Bleomycin‐induced lung injury: Revisiting an old tool to model group III PH associated with pulmonary fibrosis-Reference-Cited by-同舟云学术

Bleomycin‐induced lung injury: Revisiting an old tool to model group III PH associated with pulmonary fibrosis

Published:2023-01 Issue:1 Volume:13 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Santos‐Ribeiro Diana¹^ORCID,Lecocq Marylène¹,de Beukelaer Michele²,Bouzin Caroline²,Palmai‐Pallag Mihaly³,Yakoub Yousef³,Huaux François³,Horman Sandrine⁴,Perros Frederic⁵,Pilette Charles¹⁶,Godinas Laurent⁷

Affiliation:

1. Pneumology, ENT and Dermatology, Institute of Experimental and Clinical Research (IREC) Université catholique de Louvain (UCL) Brussels Belgium

2. Imaging Platform (2IP), Institute of Experimental and Clinical Research (IREC) Université catholique de Louvain (UCL) Brussels Belgium

3. Institute of Experimental and Clinical Research (IREC), Louvain Center for Toxicology and Applied Pharmacology Université catholique de Louvain (UCL) Brussels Belgium

4. Institute of Experimental and Clinical Research (IREC), Cardiovascular Research Unit Université catholique de Louvain (UCL) Brussels Belgium

5. Laboratoire CarMeN, UMR INSERM U1060/INRA U1397 Université Claude Bernard Lyon1 Pierre‐Bénite and Bron France

6. Departmen of Pneumology Cliniques Universitaires St‐Luc Brussels Belgium

7. Clinical Department of Respiratory Diseases, University Hospitals and Laboratory of Respiratory Diseases & ThoracicSurgery (BREATHE), Department of Chronic Diseases & Metabolism (CHROMETA) KU Leuven—University of Leuven Leuven Belgium

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12177

Reference38 articles.

1. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Pulmonary hypertension in chronic lung disease and hypoxia

3. Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups

4. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

5. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Caffeic acid ethanolamide induces antifibrosis, anti-inflammatory, and antioxidant effects protects against bleomycin-induced pulmonary fibrosis;Biomedicine & Pharmacotherapy;2024-04

2. Functional Roles of CD26/DPP4 in Bleomycin-Induced Pulmonary Hypertension Associated with Interstitial Lung Disease;International Journal of Molecular Sciences;2024-01-06

3. AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling;Peptides;2023-12

4. Insights on the mechanism of bleomycin to induce lung injury and associated in vivo models: A review;International Immunopharmacology;2023-08

5. Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?;Pharmacology & Therapeutics;2023-07